Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6947115rdf:typepubmed:Citationlld:pubmed
pubmed-article:6947115lifeskim:mentionsumls-concept:C1167395lld:lifeskim
pubmed-article:6947115lifeskim:mentionsumls-concept:C0016057lld:lifeskim
pubmed-article:6947115lifeskim:mentionsumls-concept:C0010583lld:lifeskim
pubmed-article:6947115lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:6947115lifeskim:mentionsumls-concept:C1293122lld:lifeskim
pubmed-article:6947115lifeskim:mentionsumls-concept:C0018270lld:lifeskim
pubmed-article:6947115lifeskim:mentionsumls-concept:C0301872lld:lifeskim
pubmed-article:6947115lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:6947115pubmed:issue6lld:pubmed
pubmed-article:6947115pubmed:dateCreated1982-2-25lld:pubmed
pubmed-article:6947115pubmed:abstractTextPreinjection of a low dose of cyclophosphamide (Cy) (500 microgram/mouse) either delayed or inhibited tumor appearance following the inoculation of transplantable 3-methylcholanthrene-induced fibrosarcomas in inbred male C3H/HeJ mice. This dose of Cy decreased the spleen weight by 13% and the total spleen cell count by 23%. However, the same dose could potentiate the footpad swelling reaction (FPSR) measured against Staphylococcus aureus antigen. Splenic lymphocytes from Cy-treated animals showed increased blastogenic response against phytohemagglutinin-M and bacterial lipopolysaccharide. Thus 500 micrograms Cy/animal may have depleted suppressor cell populations leading to: a) an increase in FPSR, b) increased blastogenic transformation of lymphocytes, and c) tumor growth inhibition.lld:pubmed
pubmed-article:6947115pubmed:languageenglld:pubmed
pubmed-article:6947115pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6947115pubmed:citationSubsetIMlld:pubmed
pubmed-article:6947115pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6947115pubmed:statusMEDLINElld:pubmed
pubmed-article:6947115pubmed:monthDeclld:pubmed
pubmed-article:6947115pubmed:issn0027-8874lld:pubmed
pubmed-article:6947115pubmed:authorpubmed-author:RayP KPKlld:pubmed
pubmed-article:6947115pubmed:authorpubmed-author:RaychaudhuriS...lld:pubmed
pubmed-article:6947115pubmed:issnTypePrintlld:pubmed
pubmed-article:6947115pubmed:volume67lld:pubmed
pubmed-article:6947115pubmed:ownerNLMlld:pubmed
pubmed-article:6947115pubmed:authorsCompleteYlld:pubmed
pubmed-article:6947115pubmed:pagination1341-5lld:pubmed
pubmed-article:6947115pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:6947115pubmed:meshHeadingpubmed-meshheading:6947115-...lld:pubmed
pubmed-article:6947115pubmed:meshHeadingpubmed-meshheading:6947115-...lld:pubmed
pubmed-article:6947115pubmed:meshHeadingpubmed-meshheading:6947115-...lld:pubmed
pubmed-article:6947115pubmed:meshHeadingpubmed-meshheading:6947115-...lld:pubmed
pubmed-article:6947115pubmed:meshHeadingpubmed-meshheading:6947115-...lld:pubmed
pubmed-article:6947115pubmed:meshHeadingpubmed-meshheading:6947115-...lld:pubmed
pubmed-article:6947115pubmed:meshHeadingpubmed-meshheading:6947115-...lld:pubmed
pubmed-article:6947115pubmed:meshHeadingpubmed-meshheading:6947115-...lld:pubmed
pubmed-article:6947115pubmed:meshHeadingpubmed-meshheading:6947115-...lld:pubmed
pubmed-article:6947115pubmed:meshHeadingpubmed-meshheading:6947115-...lld:pubmed
pubmed-article:6947115pubmed:meshHeadingpubmed-meshheading:6947115-...lld:pubmed
pubmed-article:6947115pubmed:meshHeadingpubmed-meshheading:6947115-...lld:pubmed
pubmed-article:6947115pubmed:year1981lld:pubmed
pubmed-article:6947115pubmed:articleTitleLow-dose cyclophosphamide inhibition of transplantable fibrosarcoma growth by augmentation of the host immune response.lld:pubmed
pubmed-article:6947115pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6947115lld:pubmed